Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.

British journal of cancer - 17 Oct 2005

Pedersen M W, Pedersen N, Ottesen L H, Poulsen H S

Abstract excerpt

Epidermal growth factor receptor (EGFR) is frequently amplified and/or mutated in a number of human tumours and abnormal signalling from this receptor is believed to contribute to the malignant phenotype seen in these tumours. Gefitinib is a small molecule inhibitor that specifically binds and inhibits the EGFR tyrosine kinase and has been shown to inhibit the growth, proliferation, survival and invasion of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion
Share to ErbB Receptors
Share to EGFR gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Phenotype

Share to Phosphorylation

Share to Signal Transduction

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 16189524
DOI: 10.1038/sj.bjc.6602793
PMCID: PMC2361662

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.PMID 16189524Read ↗

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.Semantic proximity Read ↗

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.Semantic proximity Read ↗

EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.Semantic proximity Read ↗

The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.Semantic proximity Read ↗

Growth factor receptor interplay and resistance in cancerSemantic proximity Read ↗

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cellsSemantic proximity Read ↗

Activation of extracellular-regulated kinases by normal and mutant EGF receptors.Semantic proximity Read ↗

Comparing the Epidermal Growth Factor Interaction with Four Different Cell Lines: Intriguing Effects Imply Strong Dependency of Cellular ContextSemantic proximity Read ↗

Implications of EGFR inhibition in ovarian cancer cell proliferation.Semantic proximity Read ↗

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor.Semantic proximity Read ↗

Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation.Semantic proximity Read ↗

A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.